What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
Related Articles References References Kowalski, ., et al
From making conscious dietary adjustmentsopting for smaller, more frequent meals and bland, low-fat foodsto embracing simple lifestyle changes like proper hydration and fresh air, there are many proactive steps you can take
Both sleep and stress management are important factors in managing body mass and overall well-being, especially for individuals using low dose semaglutide for maintenance
Measurement of antioxidant enzymes: superoxide dismutase, catalase, and glutathione peroxidase levels The protocols to evaluate the levels of antioxidant enzymes are of key importance to know whether alterations in antioxidant enzymes are directly linked with the diseases incidence and development or just represent secondary symptoms occurring parallel with the diseases, or even consequence of the diseases
Marie Wernecke, Fabian Stoll, Jonas Wagner, Svenja Meyhfer: The authors declare that they have no conflict of interest
